Moleculin Reports Dosing of Novel Brain Cancer Drug WP1066 in P-I trial for the treatment of Brain Tumor
Shots:
- The P-I trial is assessing WP1066 in 15 patients with relapsed brain tumor for 6 to 8mos- testing its safety and tolerability in patients at MD Anderson Cancer Centre
- WP1066 a novel STAT3i (originated from active ingredient in propolis) has shown promising results in animal studies inhibiting tumor growth with improvement in survival
- Mayo Clinic and Emory University is also evaluating WP1066 in pediatric brain tumor trials
- WP1066 inhibits STAT3 (a supporter of survival and growth of tumor cells- evasion of the immune response and metastasis to distant organs) and producing anti-cancer effects in patients
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
